Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma.
Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma.
复制标题
弥漫性脑胶质瘤中 B7-H3 (CD276) 表达和表观遗传调控的遗传和临床特征。
DOI：
10.1111/cas.13744
复制
发表时间：
2018-09
期刊：
影响因子：
5.7
通讯作者：
Jiang T
中科院分区：
文献类型：
--
作者：
Wang Z;Wang Z;Zhang C;Liu X;Li G;Liu S;Sun L;Liang J;Hu H;Liu Y;Zhang W;Jiang T
胶质瘤是最常见的脑恶性肿瘤。免疫检查点作为治疗恶性肿瘤的靶点越来越受到重视。B7‐H3已被确定为免疫检查点，显示出靶向治疗的潜在价值。我们开始使用从中国胶质瘤基因组图谱（CGGA）和癌症基因组图谱（TCGA）项目获得的高通量数据来表征脑胶质瘤中B7-H3的表达模式和生物学功能。在CGGA和TCGA数据集中，B7‐H3在高级别胶质瘤中的上调程度高于低级别胶质瘤。异柠檬酸脱氢酶（IDH）突变似乎对胶质瘤中B7-H3的表达产生显著影响，但导致II级胶质瘤和更高级别胶质瘤之间的结果截然不同。除IDH外，B7-H3启动子和microRNA-29家族的甲基化也对B7-H3表达具有潜在的调控作用。基因本体分析表明，B7-H3与有丝分裂细胞周期、细胞增殖和免疫应答相关。进一步的研究表明，B7-H3主要参与Toll样受体信号通路。生存分析表明，在CGGA和TCGA数据集中，B7‐H3是胶质瘤患者的独立不利因素。B7-H3表达受多种机制调节，并可能参与T细胞受体信号通路。较高的B7‐H3表达表明胶质瘤患者的预后较差，这需要进一步研究开发针对该免疫检查点的抑制剂，但我们仍然需要谨慎对待中枢神经系统肿瘤的免疫检查点抑制。
Gliomas are the most common malignant tumors of the brain. Immune checkpoints have been increasingly emphasized as targets for treating malignant tumors. B7‐H3 has been identified as an immune checkpoint that shows potential value for targeting therapies. We set out to characterize the expression pattern and biological function of B7‐H3 in brain gliomas using high‐throughput data obtained from the Chinese Glioma Genome Atlas (CGGA) and the Cancer Genome Atlas (TCGA) projects. B7‐H3 was upregulated more in higher‐grade gliomas than that in lower‐grade gliomas in both CGGA and TCGA datasets. Isocitrate dehydrogenase (IDH) mutation seemed to exert significant influence on B7‐H3 expression in gliomas but led to quite different results between grade II gliomas and higher‐grade gliomas. In addition to IDH, methylation of B7‐H3 promoter and microRNA‐29 family also showed a potential regulatory effect on B7‐H3 expression. Gene ontology analysis revealed that B7‐H3 was associated with mitotic cell cycle, cell proliferation and immune response. Further investigation suggested that B7‐H3 was mostly involved in the Toll‐like receptor signaling pathway. Survival analysis indicated that B7‐H3 was an independent unfavorable prognosticator for glioma patients in both CGGA and TCGA datasets. B7‐H3 expression is regulated by multiple mechanisms and is potentially involved in the T‐cell receptor signaling pathway. Higher B7‐H3 expression indicates a worse prognosis for glioma patients, which warrants further research into the development of inhibitors for targeting this immune checkpoint, but we still need to be cautious about immune checkpoint inhibition for central nervous system tumors.
登录
查看更多内容
影响因子：
13.6
作者：
Ohaegbulam KC;Assal A;Lazar-Molnar E;Yao Y;Zang X
通讯作者：
Zang X
DOI：
10.3322/caac.20069
发表时间：
2010-05
期刊：
CA: a cancer journal for clinicians
影响因子：
--
作者：
Van Meir EG;Hadjipanayis CG;Norden AD;Shu HK;Wen PY;Olson JJ
通讯作者：
Olson JJ
CGCG 成人弥漫性胶质瘤治疗临床实践指南。
影响因子：
9.7
作者：
Jiang, Tao;Mao, Ying;Wang, Qixue
通讯作者：
Wang, Qixue
272 例胶质瘤的 RNA 测序揭示了继发性胶质母细胞瘤中一种新的、复发性 PTPRZ1-MET 融合转录本。
影响因子：
7
作者：
Bao ZS;Chen HM;Yang MY;Zhang CB;Yu K;Ye WL;Hu BQ;Yan W;Zhang W;Akers J;Ramakrishnan V;Li J;Carter B;Liu YW;Hu HM;Wang Z;Li MY;Yao K;Qiu XG;Kang CS;You YP;Fan XL;Song WS;Li RQ;Su XD;Chen CC;Jiang T
通讯作者：
Jiang T
影响因子：
11.5
作者：
Lemke, Dieter;Pfenning, Philipp-Niclas;Wick, Wolfgang
通讯作者：
Wick, Wolfgang